



LBT INNOVATIONS

ASX code: LBT
lbtinnovations.com

LBT Innovations Limited (ASX:LBT)

EGM Operations Update

Brent Barnes

Chief Executive Officer & Managing Director

18th January 2017

Disclaimer

This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct.


Given these uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements due to many important factors, risk and uncertainties including, without limitation, risks associated with medical device development and manufacture, risks inherent in the extensive regulatory approval processes mandated by regulatory authorities, delays in clinical trials, future capital needs, general economic uncertainty and other risks detailed from time to time in the Company's announcements to the ASX.

Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

Our Purpose

LBT improve patient outcomes
by making healthcare more efficient.

We develop automated products that
use **intelligent imaging** and
interpretive software to improve
healthcare delivery.



Use of Proceeds

- Funds used to **ACCELERATE** the delivery to market of two products:
 1. APAS® Independence; and
 2. APAS® Incubot;
- Technology reaching the end of the development phase and now with FDA Clearance, the regulatory pathway is clear and de-risked. Therefore:
 - The Engineering development plan is being expedited as much as practically (and fiscally) possible;
 - Established partnerships with capable Engineering companies to fast track development; an example of focusing on development speed;
 - Both APAS® Independence and APAS® Incubot development projects are being done in parallel, APAS® Incubot will follow APAS® Independence.
- Accelerate the development and delivery of Analysis Modules (software that interprets the plates).

Business Outlook 2017

- APAS® technology approaching the end of a comprehensive development cycle.
- Now, with FDA Clearance, the next 12 months is about bringing product to market:
 - Production scale demonstration devices on display at global conferences starting April 2017;
 - Instruments in key opinion leader laboratories completing market acceptance testing in 2017;
 - Global distribution partner(s) confirmed; and
 - First product sales in 2017.

Product and Business Development on track, with continued positive momentum since previous market update in December 2016



Commercialisation of APAS®

Focus is on the delivery to market of laboratory instruments integrated with APAS®.

APAS® Independence and **APAS® Incubot** are automated culture plate readers integrated with APAS® and plate handling robotics:

- Demonstrations at ECCMID, Vienna (April, 2017) and ASM, San Diego (June, 2017);
- Placement of instruments in key opinion leader laboratories to validate technology in market place;
- Sales commence in 2017;
- LBT will produce the APAS® software plug-ins for the APAS® supply chain.

Joint Venture company Clever Culture Systems AG (CCS) is in discussions with international diagnostic companies to form a marketing and distribution alliance.

APAS® Independence first sales in 2017



Anticipated news flow 2017

Date	Category	News details
2017	JV CCS	Signing of alliance/distribution agreement with global partner(s) for APAS®
	JV CCS	Market acceptance testing of APAS® lab instruments
	JV CCS	APAS® Product demonstrators at European Congress of Clinical Microbiology and Infectious Diseases in Austria and American Society of Microbiology in USA.
	Joint Venture CCS	APAS® Independence first commercial sale by global alliance partner
	MicroStreak®	Signing of license or sale agreement with new partner(s)
	Imaging Platform	WoundVue® prototype complete and new phase decision point.
	Imaging Platform	Market analysis of applicable future product pipeline





LBT INNOVATIONS

Brent Barnes

CEO & Managing Director

Level 1, 300 Flinders Street
Adelaide SA 5000

P +61 (0)8 8227 1555

F +61 (0)8 8223 1775

info@lbtinnovations.com

lbtinnovations.com